- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | OKYO Pharma präsentiert Studienergebnisse zu Urcosimod auf jährlicher ASCRS-Tagung | 1 | Investing.com Deutsch | ||
| Fr | OKYO Pharma to present urcosimod NCP study results at ASCRS meeting | 1 | Investing.com | ||
| Fr | OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting | 237 | GlobeNewswire (Europe) | LONDON and NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| OKYO PHARMA Aktie jetzt für 0€ handeln | |||||
| Fr | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| Do | H.C. Wainwright reiterates Buy rating on OKYO Pharma stock with $7 price target | 1 | Investing.com | ||
| Mi | OKYO Pharma meldet erfolgreiches FDA-Treffen zur klinischen Studie mit Urcosimod | - | Investing.com Deutsch | ||
| Mi | OKYO Pharma erhält grünes Licht der FDA für entscheidende NCP-Studie | - | Investing.com Deutsch | ||
| Mi | OKYO Pharma receives FDA alignment on Phase 2b/3 trial for NCP treatment | 2 | Investing.com | ||
| Mi | OKYO Pharma Announces Successful Type C Meeting with the FDA | 203 | GlobeNewswire (Europe) | FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size and development approachLONDON and NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a... ► Artikel lesen | |
| Mo | OKYO Pharma erhält FDA-Sondergenehmigung für Urcosimod | 1 | Investing.com Deutsch | ||
| Mo | OKYO Pharma stock gets FDA compassionate use approval for urcosimod | 2 | Investing.com | ||
| 23.01. | OKYO Pharma LTD: FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain | 295 | GlobeNewswire (Europe) | LONDON and NEW YORK, Jan. 23, 2026), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases... ► Artikel lesen | |
| 23.01. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 06.01. | H.C. Wainwright reiterates Buy rating on OKYO Pharma stock at $7 target | 1 | Investing.com | ||
| 05.01. | OKYO Pharma appoints Robert Dempsey as new CEO | 1 | Investing.com | ||
| 05.01. | OKYO Pharma CEO Gary Jacob Transitions To CDO; Appoints Robert Dempsey As CEO | 2 | RTTNews | ||
| 05.01. | OKYO Pharma ernennt Robert J. Dempsey zum neuen Chief Executive Officer | 1 | Investing.com Deutsch | ||
| 05.01. | OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer | 199 | GlobeNewswire (Europe) | Accomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertise Gary S. Jacob, Ph.D., will transition to Chief Development Officer and continue to serve on... ► Artikel lesen | |
| 05.01. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 19.12.25 | OKYO Pharma: Management läutet Eröffnungsglocke der NASDAQ in New York | 2 | Investing.com Deutsch |
1 2 3 Weiter >>
59 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IDEXX LABORATORIES | 569,80 | +0,64 % | IDEXX Laboratories Q4 2025 Earnings Preview | ||
| BIOXCEL THERAPEUTICS | 1,294 | -3,29 % | BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI | NEW HAVEN, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,272 | -0,67 % | Voyager Therapeutics, Inc.: Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia | CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally "undruggable" targets by leveraging biomolecular... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,013 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 4,013 | +1,31 % | ANAVEX LIFE SCIENCES CORP: Jetzt wird's ernst am Markt! | ||
| CELLAVISION | 13,980 | -0,29 % | CellaVision: CellaVision appoints Monica Jönsson as new CFO | CellaVision announces today the appointment of Monica Jönsson as Chief Financial Officer (CFO). Monica is currently Interim CFO at CellaVision. Monica Jönsson brings extensive experience from leading... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 3,340 | 0,00 % | Precision BioSciences: Sind das jetzt Super-Schnäppchen? | Die Aktie von Precision BioSciences ist eines der wenigen Biotech-Papiere, die in diesem Jahr keinen Höhenflug erlebten. Im Gegenteil: Die Aktie hat ohne schlechte Unternehmensnews in den letzten Monaten... ► Artikel lesen | |
| ZYMEWORKS | 18,800 | -1,57 % | Zymeworks Inc.: Zymeworks Announces Participation in Upcoming Investor Conferences | VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline... ► Artikel lesen | |
| VTV THERAPEUTICS | 27,800 | 0,00 % | vTv Therapeutics Inc.: vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health | HIGH POINT, N.C., Dec. 18, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced a Phase 2 clinical study protocol developed in collaboration... ► Artikel lesen | |
| QUOIN PHARMACEUTICALS | 6,239 | +2,48 % | Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome | Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status Quoin Initiating the Establishment of a Japanese Subsidiary to Facilitate... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 4,020 | 0,00 % | Neuphoria Therapeutics, Inc.: Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions | BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies... ► Artikel lesen | |
| PLIANT THERAPEUTICS | 1,010 | -1,94 % | Pliant Therapeutics, Inc.: Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors | One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable ongoing responses with median time on treatment... ► Artikel lesen | |
| MIRA PHARMACEUTICALS | 1,100 | +3,77 % | MIRA Pharmaceuticals Initiates Multiple Ascending Dose Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication | Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track consideration MIAMI, FLORIDA / ACCESS Newswire /... ► Artikel lesen | |
| NUVATION BIO | 5,245 | -1,69 % | Truist Securities raises Nuvation Bio stock price target to $13 on Ibtrozi uptake | ||
| ONCONETIX | 1,390 | -6,08 % | Onconetix, Inc.: Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement | CINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology... ► Artikel lesen |
Das Unternehmen OKYO PHARMA LIMITED kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,050 Euro und damit +0,49 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OKYO PHARMA LIMITED finden Sie auf Wallstreet Online.